Here's Why M&A Has Tesaro's Stock Soaring 40% In 2017

Here's Why M&A Has Tesaro's Stock Soaring 40% In 2017


That's impressive, but there could be room to run higher. Why? Because Tesaro could be about to land its second FDA approval, and this next approval could be a biggie.



from Biotech News